These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Cyclooxygenase-2 selective non-steroidal anti-inflammatory drugs (etodolac, meloxicam, celecoxib, rofecoxib, etoricoxib, valdecoxib and lumiracoxib) for osteoarthritis and rheumatoid arthritis: a systematic review and economic evaluation. Chen YF; Jobanputra P; Barton P; Bryan S; Fry-Smith A; Harris G; Taylor RS Health Technol Assess; 2008 Apr; 12(11):1-278, iii. PubMed ID: 18405470 [TBL] [Abstract][Full Text] [Related]
4. Current perspective on the cardiovascular effects of coxibs. Konstam MA; Weir MR Cleve Clin J Med; 2002; 69 Suppl 1():SI47-52. PubMed ID: 12086293 [TBL] [Abstract][Full Text] [Related]
5. Temporal relationship between use of NSAIDs, including selective COX-2 inhibitors, and cardiovascular risk. Motsko SP; Rascati KL; Busti AJ; Wilson JP; Barner JC; Lawson KA; Worchel J Drug Saf; 2006; 29(7):621-32. PubMed ID: 16808554 [TBL] [Abstract][Full Text] [Related]
6. Cyclooxygenase-2 inhibitors: a painful lesson. Sanghi S; MacLaughlin EJ; Jewell CW; Chaffer S; Naus PJ; Watson LE; Dostal DE Cardiovasc Hematol Disord Drug Targets; 2006 Jun; 6(2):85-100. PubMed ID: 16787194 [TBL] [Abstract][Full Text] [Related]
7. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk--where are we now? Spektor G; Fuster V Nat Clin Pract Cardiovasc Med; 2005 Jun; 2(6):290-300. PubMed ID: 16265533 [TBL] [Abstract][Full Text] [Related]
8. Anti-inflammatory drugs in the 21st century. Rainsford KD Subcell Biochem; 2007; 42():3-27. PubMed ID: 17612044 [TBL] [Abstract][Full Text] [Related]
9. Risk of cardiovascular events associated with selective COX-2 inhibitors. Mukherjee D; Nissen SE; Topol EJ JAMA; 2001 Aug 22-29; 286(8):954-9. PubMed ID: 11509060 [TBL] [Abstract][Full Text] [Related]
10. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Weir MR; Sperling RS; Reicin A; Gertz BJ Am Heart J; 2003 Oct; 146(4):591-604. PubMed ID: 14564311 [TBL] [Abstract][Full Text] [Related]
11. Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia. Jordan F; Quinn TJ; McGuinness B; Passmore P; Kelly JP; Tudur Smith C; Murphy K; Devane D Cochrane Database Syst Rev; 2020 Apr; 4(4):CD011459. PubMed ID: 32352165 [TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials. Schmidt M; Sørensen HT; Pedersen L Drug Saf; 2022 Sep; 45(9):983-994. PubMed ID: 35909207 [TBL] [Abstract][Full Text] [Related]
13. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Valat JP; Deray G; Héloire F Presse Med; 2006 Sep; 35(9 Spec No 1):1S25-34. PubMed ID: 17078592 [TBL] [Abstract][Full Text] [Related]
14. Differential effects of selective cyclooxygenase-2 inhibitors on vascular smooth muscle ion channels may account for differences in cardiovascular risk profiles. Brueggemann LI; Mackie AR; Mani BK; Cribbs LL; Byron KL Mol Pharmacol; 2009 Nov; 76(5):1053-61. PubMed ID: 19605525 [TBL] [Abstract][Full Text] [Related]
15. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Fosslien E Ann Clin Lab Sci; 2005; 35(4):347-85. PubMed ID: 16254252 [TBL] [Abstract][Full Text] [Related]
16. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles. Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562 [TBL] [Abstract][Full Text] [Related]
17. Non-steroidal anti-inflammatory drugs and the risk of cardiovascular diseases: are we going to see the revival of cyclooxygenase-2 selective inhibitors? Głuszko P; Bielińska A Pol Arch Med Wewn; 2009 Apr; 119(4):231-5. PubMed ID: 19413182 [TBL] [Abstract][Full Text] [Related]
18. Cardiovascular issues of COX-2 inhibitors and NSAIDs. Wong M; Chowienczyk P; Kirkham B Aust Fam Physician; 2005 Nov; 34(11):945-8. PubMed ID: 16299629 [TBL] [Abstract][Full Text] [Related]
19. [Are there any differences in the cardiovascular tolerance between classical NSAIDs and coxibs?]. Valat JP; Deray G; Héloire F Presse Med; 2006 Sep; 35 Suppl 1():25-34. PubMed ID: 17870550 [TBL] [Abstract][Full Text] [Related]
20. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers. Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]